Feinstein Institute for Medical Research at Northwell Health, Manhasset, New York.
Harvard Medical School, Boston, Massachusetts.
JAMA. 2021 May 18;325(19):1965-1977. doi: 10.1001/jama.2021.6238.
Colorectal cancer is the third leading cause of cancer death for both men and women, with an estimated 52 980 persons in the US projected to die of colorectal cancer in 2021. Colorectal cancer is most frequently diagnosed among persons aged 65 to 74 years. It is estimated that 10.5% of new colorectal cancer cases occur in persons younger than 50 years. Incidence of colorectal cancer (specifically adenocarcinoma) in adults aged 40 to 49 years has increased by almost 15% from 2000-2002 to 2014-2016. In 2016, 26% of eligible adults in the US had never been screened for colorectal cancer and in 2018, 31% were not up to date with screening.
To update its 2016 recommendation, the US Preventive Services Task Force (USPSTF) commissioned a systematic review to evaluate the benefits and harms of screening for colorectal cancer in adults 40 years or older. The review also examined whether these findings varied by age, sex, or race/ethnicity. In addition, as in 2016, the USPSTF commissioned a report from the Cancer Intervention and Surveillance Modeling Network Colorectal Cancer Working Group to provide information from comparative modeling on how estimated life-years gained, colorectal cancer cases averted, and colorectal cancer deaths averted vary by different starting and stopping ages for various screening strategies.
Asymptomatic adults 45 years or older at average risk of colorectal cancer (ie, no prior diagnosis of colorectal cancer, adenomatous polyps, or inflammatory bowel disease; no personal diagnosis or family history of known genetic disorders that predispose them to a high lifetime risk of colorectal cancer [such as Lynch syndrome or familial adenomatous polyposis]).
The USPSTF concludes with high certainty that screening for colorectal cancer in adults aged 50 to 75 years has substantial net benefit. The USPSTF concludes with moderate certainty that screening for colorectal cancer in adults aged 45 to 49 years has moderate net benefit. The USPSTF concludes with moderate certainty that screening for colorectal cancer in adults aged 76 to 85 years who have been previously screened has small net benefit. Adults who have never been screened for colorectal cancer are more likely to benefit.
The USPSTF recommends screening for colorectal cancer in all adults aged 50 to 75 years. (A recommendation) The USPSTF recommends screening for colorectal cancer in adults aged 45 to 49 years. (B recommendation) The USPSTF recommends that clinicians selectively offer screening for colorectal cancer in adults aged 76 to 85 years. Evidence indicates that the net benefit of screening all persons in this age group is small. In determining whether this service is appropriate in individual cases, patients and clinicians should consider the patient's overall health, prior screening history, and preferences. (C recommendation).
结直肠癌是男性和女性癌症死亡的第三大主要原因,预计 2021 年美国将有 52980 人死于结直肠癌。结直肠癌最常发生在 65 至 74 岁的人群中。据估计,50 岁以下人群中有 10.5%的新结直肠癌病例。40 至 49 岁成年人的结直肠癌(特别是腺癌)发病率从 2000-2002 年到 2014-2016 年增加了近 15%。2016 年,美国符合条件的成年人中有 26%从未接受过结直肠癌筛查,2018 年有 31%未及时进行筛查。
为了更新其 2016 年的建议,美国预防服务工作组(USPSTF)委托进行了一项系统评价,以评估对 40 岁及以上成年人进行结直肠癌筛查的益处和危害。该评价还检查了这些发现是否因年龄、性别或种族/民族而异。此外,与 2016 年一样,USPSTF 委托癌症干预和监测建模网络结直肠癌工作组提供一份报告,提供来自比较建模的信息,说明不同筛查策略的不同起始和停止年龄对估计的获益寿命、结直肠癌病例的减少和结直肠癌死亡的减少有何影响。
无结直肠癌、腺瘤性息肉或炎症性肠病既往诊断;无个人诊断或已知遗传疾病家族史,这些疾病使他们有很高的终生结直肠癌风险(如林奇综合征或家族性腺瘤性息肉病)的 45 岁或以上的无症状成年人。
USPSTF 非常确定地得出结论,在 50 至 75 岁的成年人中进行结直肠癌筛查有很大的净收益。USPSTF 非常确定地得出结论,在 45 至 49 岁的成年人中进行结直肠癌筛查有适度的净收益。USPSTF 非常确定地得出结论,对以前筛查过的 76 至 85 岁成年人进行结直肠癌筛查有较小的净收益。从未接受过结直肠癌筛查的成年人更有可能受益。
USPSTF 建议在所有 50 至 75 岁的成年人中进行结直肠癌筛查。(A 级推荐)USPSTF 建议在 45 至 49 岁的成年人中进行结直肠癌筛查。(B 级推荐)USPSTF 建议对 76 至 85 岁的成年人选择性地进行结直肠癌筛查。证据表明,对所有该年龄段人群进行筛查的净收益很小。在确定该服务是否适用于个别病例时,患者和临床医生应考虑患者的整体健康状况、既往筛查史和偏好。(C 级推荐)。